Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ashmore assets under management up $1.4bn in Q4

(Sharecast News) - Asset manager Ashmore said on Monday that assets under management increased by $1.4bn over the three months ended 30 June, made up of a positive investment performance of $2.2bn and net outflows of $800.0m. Ashmore said net flows improved from Q3, with "significantly lower" redemptions, against a backdrop of "continuing trade tensions and geopolitical uncertainty", while subscription levels were consistent.

Fixed income AuM was up 2% quarter-on-quarter at $38.5bn, equities AuM increased by 10% to $7.5bn, and total AuM rose 3% to $47.6bn.

However, the FTSE 250-listed group also cautioned that investors' risk appetite "generally remained subdued", given macro events.

Chief executive Mark Coombs said: "Ashmore's diversified product range and delivery of investment outperformance for clients means it is well-positioned to participate in the reallocation opportunity, as investors move back up to target weights and then address the structural underweights compared with EM's representation in global indices."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.